BioCentury
ARTICLE | Financial News

Adynxx raises $16M in series B

January 10, 2017 11:59 PM UTC

Pain company Adynxx Inc. (San Francisco, Calif.) raised $16 million in a series B round led by new investor TPG Biotech. Existing investor Domain Associates also participated.

Adynxx said it plans to start a Phase II study of lead program AYX1 to prevent chronic pain following surgery. The company did not respond to an inquiry about the trial's timeline. AYX1 is a small synthetic dsDNA inhibitor of early growth response 1 (EGR1)...

BCIQ Company Profiles

Adynxx Inc.

BCIQ Target Profiles

Early growth response 1 (EGR1)